Thinly traded nano cap Trovagene (NASDAQ:TROV) is up 14% premarket on light volume in response to its announcement that it has completed its Phase 1b clinical trial evaluating lead drug onvansertib, combined with chemo, for the treatment of acute myeloid leukemia (AML).
Responses were observed in 24% (n=5/21) of participants.
A 32-subject Phase 2 study is now recruiting patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.